Drugs / NT-175
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05877599 | Jul 2023 → Jul 2029 expected | breast cancer, colorectal carcinoma, head and neck squamous cell carcinoma, myeloid neoplasm +3 | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT-175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877599 ↗ |
| Modality | Cell therapy | “an autologous T cell therapy product genetically engineered” NCT05877599 ↗ |
| Target | TP53 | “targeting TP53 R175H mutant malignancies” NCT05877599 ↗ |